Recombinant interleukin 2 therapy in severe combined immunodeficiency disease
R Pahwa, T Chatila, S Pahwa, C Paradise, N K Day, R Geha, S A Schwartz, H Slade, N Oyaizu, R A Good, R Pahwa, T Chatila, S Pahwa, C Paradise, N K Day, R Geha, S A Schwartz, H Slade, N Oyaizu, R A Good
Abstract
Severe combined immunodeficiency disease (SCID) is a congenital disorder of severe B- and T-lymphocyte dysfunction in which several pathogenic mechanisms have been identified. The present study describes a female child with SCID who had a primary defect in the ability of T cells to secrete interleukin 2 (IL-2). B- and T-cell numbers were normal, but their functions were severely deficient. Mitogen and antigen-driven lymphoproliferative responses were diminished but were correctable in vitro with recombinant IL-2 (rIL-2). The patient's phytohemagglutinin-stimulated lymphocytes expressed IL-2 receptors normally. Despite the presence of the gene for IL-2, the patient's cells were grossly deficient in messenger RNA for IL-2 and endogenous IL-2 production. Pokeweed mitogen-driven B-cell differentiation was decreased and was not corrected by the addition of normal T cells to the B cells. Two attempts at immune reconstitution by haploidentical bone marrow transplantation failed. Therapy with rIL-2 (30,000 units/kg, given daily i.v.) resulted in marked clinical improvement as well in improved T-cell functions. The child, now 3 yr old, has been on rIL-2 therapy for 2 yr and receives rIL-2 (30,000 units/kg) three times weekly at home. This case study points to a new direction in the treatment of such disorders with rIL-2.
References
- Pediatrics. 1985 Dec;76(6):914-7
- Clin Immunol Immunopathol. 1987 Aug;44(2):235-47
- J Immunol. 1986 May 1;136(9):3282-7
- Science. 1986 May 9;232(4751):727-32
- Annu Rev Med. 1986;37:173-8
- Immunol Rev. 1987 Feb;95:137-59
- Immunol Rev. 1987 Feb;95:5-36
- Immunol Rev. 1987 Feb;95:89-111
- N Engl J Med. 1975 Aug 28;293(9):424-8
- Science. 1976 Sep 10;193(4257):1007-8
- Lancet. 1976 Dec 11;2(7998):1270-2
- Nature. 1977 Jul 14;268(5616):154-6
- J Immunol. 1978 Nov;121(5):1951-5
- J Clin Invest. 1979 Dec;64(6):1632-41
- J Exp Med. 1980 Jun 1;151(6):1551-6
- J Clin Invest. 1980 Sep;66(3):543-50
- Immunol Rev. 1980;51:337-57
- J Immunol. 1982 Feb;128(2):679-83
- J Clin Immunol. 1982 Jul;2(3):205-13
- J Clin Immunol. 1983 Jan;3(1):1-13
- Nature. 1983 Mar 24-30;302(5906):305-10
- Clin Exp Immunol. 1983 Feb;51(2):338-44
- J Immunol. 1983 Jun;130(6):2644-50
- Proc Natl Acad Sci U S A. 1983 Jun;80(11):3444-7
- J Immunol. 1983 Sep;131(3):1205-8
- Cell. 1984 Apr;36(4):897-906
- Proc Natl Acad Sci U S A. 1984 Mar;81(5):1509-13
- Proc Natl Acad Sci U S A. 1984 Jul;81(13):4169-73
- Proc Natl Acad Sci U S A. 1984 Aug;81(15):4945-9
- J Immunol. 1984 Oct;133(4):1920-4
- Nature. 1984 Oct 18-24;311(5987):626-31
- Ann Intern Med. 1984 Dec;101(6):757-63
- Cancer Invest. 1985;3(1):35-49
- J Exp Med. 1985 Jun 1;161(6):1513-24
- J Immunol. 1985 Oct;135(4):2249-55
- J Exp Med. 1985 Sep 1;162(3):823-38
- Clin Immunol Immunopathol. 1988 Jan;46(1):24-36
- J Clin Invest. 1986 Apr;77(4):1224-32
Source: PubMed